A phase 2, international, multicenter, open-labeled, randomized trial of PAlbociclib and fulvestrant vs. Standard oral capecitabine In Patients with Hormone receptor positive/HER2 negative Advanced breast cancer and documented Endocrine resistance (PASIPHAE)

Trial Profile

A phase 2, international, multicenter, open-labeled, randomized trial of PAlbociclib and fulvestrant vs. Standard oral capecitabine In Patients with Hormone receptor positive/HER2 negative Advanced breast cancer and documented Endocrine resistance (PASIPHAE)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Fulvestrant (Primary) ; Palbociclib (Primary) ; Capecitabine; Goserelin
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms PASIPHAE
  • Most Recent Events

    • 16 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top